Karyopharm (KPTI) Sell-Off Overdone, Leerink Partners Says
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Karyopharm Therapeutics (KPTI) Moves to Session Lows
August 10, 2015 2:00 PM EDTKaryopharm Therapeutics (NASDAQ: KPTI) has moved to session lows following Q2 results reported before markets opened Monday. Shares are down over 39 percent and reached a 52-week low at $13.36 today. Volume at over 1.7 million shares compares with average daily volume of about 335,000 shares.
KPTI... More
Karyopharm Therapeutics (KPTI) Misses Q2 EPS by 15c
August 10, 2015 7:41 AM EDTKaryopharm Therapeutics (NASDAQ: KPTI) reported Q2 EPS of ($0.92), $0.15 worse than the analyst estimate of ($0.77). Revenue for the quarter came in at $150 thousand versus the consensus estimate of $90 thousand.
Financial Outlook
Based on current operating plans, Karyopharm expects that its existing... More
